1. Utility of PET, CT, and EUS to Identify Pathologic Responders in Esophageal Cancer 
Stephen G. Swisher, MD, Mary Maish, MD, Jeremy J. Erasmus, MD, Arlene M. Correa, PhD, Jaffer A. Ajani, MD, Robert Bresalier, MD, Ritsuko Komaki, MD, Homer Macapinlac, MD, Reginald F. Munden, MD, Joe B. Putnam, MD, David Rice, MD, W.Roy Smythe, MD, Ara A. Vaporciyan, MD, Garrett L. Walsh, MD, Tsung T. Wu, MD, Jack A. Roth, MD 
The Annals of Thoracic Surgery 
Volume 78, Issue 4, Pages (October 2004)
DOI: /j.athoracsur

2. Fig 1
Kaplan-Meier survival analysis of esophageal cancer patients according to post-CRT PET SUV at primary tumor site (p = 0.01). (CRT = concurrent chemotherapy and radiotherapy; PET = positron emission tomography; SUV = standardized uptake value.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )

3. Fig 2
Kaplan-Meier survival analysis of esophageal cancer patients according to post-CRT EUS size (mm) at primary tumor site (p = 0.17). (CRT = concurrent chemotherapy and radiotherapy; EUS = endoscopic ultrasonography.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )

4. Fig 3
Kaplan-Meier survival analysis of esophageal cancer patients according to post-CRT CT scan thickness at primary tumor site (p = 0.20). (CRT = concurrent chemotherapy and radiotherapy; CT = computed tomographic scan.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )